BriaCell Therapeutics Corp. (NASDAQ:BCTX) Short Interest Up 245.7% in December

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the target of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,380,000 shares, an increase of 245.7% from the November 30th total of 688,400 shares. Based on an average daily volume of 2,490,000 shares, the days-to-cover ratio is presently 1.0 days. Approximately 6.0% of the company’s stock are sold short.

BriaCell Therapeutics Stock Performance

BCTX stock traded up $0.02 during mid-day trading on Friday, reaching $0.56. The company had a trading volume of 517,645 shares, compared to its average volume of 1,625,234. BriaCell Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $5.97. The company has a market capitalization of $24.22 million, a price-to-earnings ratio of -0.48 and a beta of 1.46. The firm has a fifty day simple moving average of $0.76 and a 200 day simple moving average of $0.82.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings data on Monday, December 16th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). As a group, analysts predict that BriaCell Therapeutics will post -1.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of BriaCell Therapeutics in a research note on Thursday, December 12th.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new position in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned about 0.44% of BriaCell Therapeutics at the end of the most recent reporting period. 15.42% of the stock is owned by institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.